• metastatic/advanced - colorectal cancer (mCRC)
• mCRC - 1st line (L1) 1
• mCRC - 2nd line (L2) 3
• endometrial cancer 1
• esophageal cancer (EC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• pembrolizumab based treatment
• pembrolizumab plus lenvatinib
• VEGF(R) inhibitor
• lenvatinib
• lenvatinib in association

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs anthracyclines
• vs doxorubicin
• vs taxanes
• vs paclitaxel
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs paclitaxel plus carboplatin

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  endometrial cancer;